Literature DB >> 9028584

Effects of nitric oxide synthase blockade on esophageal peristalsis and the lower esophageal sphincter in the cat.

S Xue1, D Valdez, P I Collman, N E Diamant.   

Abstract

The present study explores the role of nitric oxide (NO) in control of esophageal peristalsis and lower esophageal sphincter (LES) function in the cat. Studies were performed on 20 ketamine-anesthetized cats with manometric recording at the LES, 0, 2, 4, and 6 cm above the LES (smooth muscle section), and 12 and (or) 14 cm above the LES (striated muscle section). L-Ng-Nitro-arginine (L-NNA, 10(-6)-10(-4) mol/kg) was given intravenously, and the effects on swallow-induced esophageal peristalsis were assessed. (i) L-NNA increased the velocity of swallow-induced peristalsis in the smooth muscle esophagus; the effect was dose dependent, more prominent distally, and completely reversed by L-arginine (10(-3) mol/kg). (ii) L-NNA decreased the amplitude of peristaltic contraction in the very distal esophagus; the decrease also was dose dependent but not returned to normal by L-arginine. (iii) L-NNA inhibited LES relaxation (reversed by L-arginine) and decreased the LES "after-contraction" amplitude (unaffected by L-arginine). (iv) L-NNA was associated with the appearance of repetitive contractions. Basal LES tone was unaffected by L-NNA. In conclusion, NO is an important mediator for the timing of peristalsis in the distal smooth muscle esophagus and for LES relaxation in the cat, a species whose contraction amplitude is largely determined by cholinergic excitation. The role of NO in controlling esophageal body and LES contraction amplitude, and in preventing repetitive contractions, requires further study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9028584     DOI: 10.1139/cjpp-74-11-1249

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  9 in total

Review 1.  Neuromuscular control of esophageal peristalsis.

Authors:  H Park; J L Conklin
Journal:  Curr Gastroenterol Rep       Date:  1999-06

2.  Population based study to assess prevalence and risk factors of gastroesophageal reflux disease in a high altitude area.

Authors:  Sushil Kumar; Saurabh Sharma; Tsering Norboo; Diskit Dolma; Angchuk Norboo; Tsering Stobdan; S Rohatgi; K Munot; Vineet Ahuja; Anoop Saraya
Journal:  Indian J Gastroenterol       Date:  2010-12-23

Review 3.  Neuronal Control of Esophageal Peristalsis and Its Role in Esophageal Disease.

Authors:  K Nikaki; A Sawada; A Ustaoglu; D Sifrim
Journal:  Curr Gastroenterol Rep       Date:  2019-11-23

4.  Dominant role of interstitial cells of Cajal in nitrergic relaxation of murine lower oesophageal sphincter.

Authors:  Dieter Groneberg; Eugen Zizer; Barbara Lies; Barbara Seidler; Dieter Saur; Martin Wagner; Andreas Friebe
Journal:  J Physiol       Date:  2014-12-08       Impact factor: 5.182

5.  Esophageal motility disorders (distal esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter): modern management.

Authors:  Radu Tutuian; Donald O Castell
Journal:  Curr Treat Options Gastroenterol       Date:  2006-07

6.  Nitric oxide activation of a potassium channel (BK(Ca)) in feline lower esophageal sphincter.

Authors:  Marie-Claude L'Heureux; Ahmad Muinuddin; Herbert Y Gaisano; Nicholas E Diamant
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

7.  Role of nitric oxide during swallow-induced esophageal shortening in cats.

Authors:  D Sifrim; R Lefebvre
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

Review 8.  Regulation of basal tone, relaxation and contraction of the lower oesophageal sphincter. Relevance to drug discovery for oesophageal disorders.

Authors:  R Farré; D Sifrim
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

9.  Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux.

Authors:  M Nilsson; R Johnsen; W Ye; K Hveem; J Lagergren
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.